Expand all sections

Fezolinetant

unknown

Extended indication Behandeling van matige tot ernstige menopauze gerelateerde vasomotorische symptomen
Therapeutic value No estimate possible yet
Registration phase Clinical trials

Product

Active substance Fezolinetant
Domain Metabolism and Endocrinology
Reason of inclusion New medicine (specialité)
Main indication Metabolic diseases
Extended indication Behandeling van matige tot ernstige menopauze gerelateerde vasomotorische symptomen
Proprietary name unknown
Manufacturer Astellas
Mechanism of action Receptor antagonist
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Extramural (GVS)
Additional comments Neurokinine-3-receptor antagonist

Registration

Registration route Centralised (EMA)
ATMP No
Submission date November 2022
Expected Registration February 2024
Orphan drug No
Registration phase Clinical trials

Therapeutic value

Current treatment options De standaard geneesmiddelbehandeling voor vasomotorische symptomen in de menopauze is hormoontherapie met een combinatie van oestrogeen en progesteron, of oestrogeen alleen.
Therapeutic value No estimate possible yet
Frequency of administration 1 times a day

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension No
References adisinsght

Other information

There is currently no futher information available.